Clinical Laserthermia Systems Ab Class B · OMXSTO:CLS_B
Clinical Laserthermia Systems Ab Class B — Shareholder Meeting (May 2018)
18 slides from Clinical Laserthermia Systems Ab Class B's shareholder meeting presentation, May 18, 2018
Slide 1: Välkommen till Extra Bolagsstämma
Välkommen till Extra Bolagsstämma Clinical Laserthermia Systems AB | www.clinicallaser.se | www.imilt.se Clinical Laserthermia Systems AB | www.clinicallaser.se | www.imilt.se
Slide 2: This is CLS
This is CLS TRANBERG®|Thermal Therapy System and unique fiber technology For heat-induced cancer treatment. Optimized for precise and controlled killing of local tumor cells. imILT and FLA imILT: immunostimulating treatment of metastatic cancer FLA: ablation treatment of cancer tumors Benefits Can b
Slide 3: The value we offer
The value we offer For the clinician: a safe, easy-to-use system for precise, controlled and gentle thermal treatment with the immuno-stimulating imILT protocol or with MRI- guided laser ablation. For the patient: a gentle and efficient treatment with few known side-effects For the hospital: lower o
Slide 4: The products
The products Medical laser device with proprietary therapeutic protocol – imILT®. Measures, controls and delivers, with high precision, laser induced heat. Single use applicator kits and laser fiber optimized for the intra-operative or image guided percutaneous procedures. CE-marked and 510(k) clear
Slide 5: Unique fiber technology
Unique fiber technology • In March 2017 CLS buys patents and unique expertise in microstructuring of laser fiber from Laser- und Medizin-Technologie GmbH (LMTB) and extends its collaboration with Advandced Fiber Tools (AFT) • CLS and LMTB previously jointly developed the technology that is the core
Slide 6: How does imILT® work?
How does imILT® work? Activated cytotoxic T cells home in on and kill tumor tissue throughout the body (5). Setting an immunological memory Clinical Laserthermia Systems AB | www.clinicallaser.se | www.imilt.se
Slide 7: Positive trend for imILT®
Positive trend for imILT® • Analysis of 7 of these patients today show average survival of about 14 months • Reports on survival on similar patient group shows significantly below 12 months – even 9 months • Safe and controlled procedure • First Post-Market report completed • First H2020 report file
Slide 8: Image guided laser ablation
Image guided laser ablation • Image-guided laser ablation – primarily for treatment of early localized prostate cancer (PCA). • Same principle as imILT • Evaluation at UTMB with the primary objective of introduce CLS's single-use materials for FLA • Also evaluated for vascular malformations at US ho
Slide 9: Ongoing clinical studies FLA
Ongoing clinical studies FLA • Early stage prostate cancer – Toronto General Hospital Initiated by the hospital. 25 patients. Starting in April 2018 • Provides data supporting our marketing and sales in the U.S. and Canada Clinical Laserthermia Systems AB | www.clinicallaser.se | www.imilt.se
Slide 10: Recent achievements
Recent achievements • imILT study on malignant melanoma opens for new patient group April 2018 • FLA study on 25 patients with prostate cancer started in Toronto April 2018 • Analysis of 7 of patients w pancreatic cancer show average survival of 14 months after imILT treatment March 2018 • Second TR
Slide 11: Målsättning imILT®
Målsättning imILT® TRANBERG® för bildstyrd immunstimulerande lasertermoterapi för malign tumörsjukdom • Under 2018 är målsättningen att slutföra pågående kliniska studier på CT-/ultraljudsstyrd imILT®-behandling med våra TRANBERG®- produkter för att, med dessa resultat som underlag, fatta beslut om
Slide 12: Målsättning FLA
Målsättning FLA TRANBERG® för bildstyrd fokuserad laserablation av lokaliserad benign och tidigt malign tumörsjukdom • Under 2018 är målsättningen att i USA bredda lanseringen av TRANBERG®- portföljen för bildstyrd fokuserad laserablation (FLA) av lokaliserad prostatacancer. För att nå detta mål avs
Slide 13: Company development 2018-2019
Company development 2018-2019 • Build sales organization in the U.S. • Build sales organization in Europe • Continue business development by: - software project for complete offer in MR guided treatment - fusion imaging project, combining biopsy w. thermo therapy • Continue clinical development by:
Slide 14: Next Step - Focal Therapy with Real Time Control
Next Step - Focal Therapy with Real Time Control Technology Platform Delivering Customized Precise Ablation Therapy for MR Imaging Stereotaxi Energy Delivery Specific Organs Ablation Reduced Short Targeting Instrument Energy Side Recovery Monitoring. Nav & Pos. Delivery Effects Time & Control 1 2 3
Slide 15: TRANBERG® – In Focal Therapy for Prostate
TRANBERG® – In Focal Therapy for Prostate MR Thermometry Navig./Pos. Workstation TRANBERG®| Navig./Position. TRANBERG®|TT System Applicator Kit In-bore HW MR Scanner / Patient Clinical Laserthermia Systems AB | www.clinicallaser.se
Slide 16: Förestående nyemission
Förestående nyemission Bakgrund och motiv i sammandrag Kapitalanvändning • Parallellt med Bolagets pågående studier • Likviden från Företrädesemissionen avses gällande imILT har Bolaget påbörjat användas till följande: utvärdering av teknologi och produkter för • Fortsatt marknadsetablering, vilket
Slide 17: Sammanfattning
Sammanfattning • Genom företrädesemissionen tillförs CLS cirka • Styrelsen föreslår vidare att bolagsstämman 61 MSEK, före emissionskostnader. beslutar om ett emissionsbemyndigade för Företrädesemissionen omfattar högst 7 173 styrelsen att besluta om en s.k. 935 nya B-aktier i CLS. övertilldelningse
Slide 18: Thank you!
Thank you! www.clinicallaser.se
Clinical Laserthermia Systems — Shareholder Meeting (May 2018) on 6ix